Clinical trials
Breast clinical trials
Below are recruiting breast clinical trials, each written for real people, not researchers. We’re tracking 2,691 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07047365RecruitingPhase 3
New drug for HER2-positive advanced breast cancer
This trial tests a new medicine called TQB2930 for people with advanced breast cancer that is HER2-positive. It is for those who have already had at least two prior anti-HER2 treatments and are willing to also receive chemotherapy chosen by their doctor.
Bengbu, AnhuiAges 18–75 - NCT07213271Recruiting
Exercise study for obese breast cancer survivors
This study tests whether a physical exercise program can improve metabolism, gut health, fitness, and quality of life in obese women who have completed breast cancer treatment at least one year ago.
BratislavaAges 25–70 - NCT07340398RecruitingPhase 2
Testing new drug combos for HER2-positive breast cancer not responding to first therapy
This trial tests a new combination of drugs for people with HER2-positive early breast cancer whose tumors did not respond well to the first round of standard targeted therapy plus chemo. The goal is to see if switching to trastuzumab-rezetecan plus pertuzumab or a different chemo combo (nab-paclitaxel, carboplatin, trastuzumab, and pyrotinib) can shrink the tumor before surgery.
HangzhouAges 18–75 - NCT04133077Recruiting
Biobank study using tumor tissue to grow patient tumor models
This study takes small samples of your breast tumor tissue after (or during) treatment and grows them in lab animals to better study breast cancer. It may help researchers test future ideas for treating aggressive breast cancer types like triple-negative or Luminal B.
Clermont-Ferrand, Puy-de-DômeAges 18 years+ - NCT07721753Recruiting
Online exercise and therapy for breast cancer mood
This study tests an online program that combines fun video-game exercises with talk therapy to help breast cancer patients who feel depressed or anxious. It takes place in Malaysia and is for Chinese-speaking adults.
Xinxiang, HenanAges 18 years+ - NCT04174352RecruitingEarly Phase 1
FES scan to guide tamoxifen for metastatic breast cancer
This early-phase study uses a special PET scan (FES PET/CT) to better match tamoxifen treatment to people with estrogen-receptor–positive breast cancer that has spread. It aims to see whether the scan results can help optimize tamoxifen use and potentially improve outcomes.
Madison, WisconsinAges 19 years+ - NCT07340424RecruitingEarly Phase 1
Study of 225Ac-TR2205 for triple-negative breast cancer
This trial tests a new radioactive drug called 225Ac-TR2205 for people with triple-negative breast cancer that has spread. The goal is to see if it is safe and tolerable. It may be an option if you have tried at least two other treatments, including one for metastatic disease.
Jinan, ShandongAges 18 years+ - NCT07681323Recruiting
Timing of ctDNA Testing in Advanced Breast Cancer
This study looks at whether a simple blood test (ctDNA test) can help track advanced breast cancer over time. It aims to see how well the test works for monitoring the disease.
BeijingAges 18 years+ - NCT07673029RecruitingPhase 3
Comparing two treatments for HER2-positive breast cancer
This trial compares a new drug, GQ1005, with an existing treatment called T-DM1 for people with HER2-positive breast cancer that has spread or cannot be removed by surgery. The goal is to see which one works better for those who have already received certain other treatments.
Bengbu, AnhuiAges 18–75 - NCT07396324RecruitingPhase 2
A new drug before surgery for HR+ HER2- breast cancer
This trial tests whether the drug QL1706, given before surgery, can help treat hormone receptor positive and HER2-negative breast cancer. It is for people who have not yet had cancer spread to other parts of the body.
ShanghaiAges 18 years+ - NCT04278469Recruiting
Study for early breast cancer patients with low-risk genes
This trial studies early, hormone receptor–positive, HER2-negative breast cancer and looks at a group with “high clinical risk” but “low genetic (tumor) risk.” It may help researchers understand which patients may benefit most from treatment decisions guided by genetic tumor testing.
SeoulAges 19–80 - NCT07527741Recruiting
HER2-Positive Breast Cancer Treatment Patterns Study
This study tracks how patients with HER2-positive early-stage breast cancer receive treatment and stick to their treatment plan after their care moves to local hospitals. The trial helps doctors understand whether patients follow through with their recommended therapy when treated closer to home.
Loznica, Bolnička 65Ages 18 years+ - NCT07540533RecruitingPhase 2
Toripalimab Plus Chemotherapy for Advanced HER2-Negative Breast Cancer
This trial tests a combination of toripalimab (an immunotherapy drug) with chemotherapy to treat advanced breast cancer that is HER2-negative. The goal is to see if this combination can help slow or stop cancer growth in patients who have already tried other treatments.
Zhengzhou, HenanAges 18 years+ - NCT07531693Recruiting
Improving Outcomes in Early Hormone-Positive Breast Cancer
This study follows women taking abemaciclib (a targeted cancer drug) for early-stage hormone-receptor-positive breast cancer to understand how the treatment affects their quality of life and health outcomes. The goal is to improve care for people in this situation.
Erlangen, BavariaAges 18 years+ - NCT04794075Recruiting
Nursing and education support for women on hormone breast therapy
This trial tests a structured nursing and education program to support people with non-metastatic breast cancer who take hormone-blocking treatment. It may help you manage side effects and stay supported during follow-up, using online questionnaires and scheduled sessions.
Bourg-en-BresseAges 18–75 - NCT05507879Recruiting
Breast cancer heart monitoring to predict heart damage risk
This trial studies how a blood test marker (TRPC6) may help predict and prevent heart muscle damage and heart failure related to some breast cancer medicines. You may join if you’re starting or have received treatment that can stress the heart, or if you already have signs of treatment-related heart problems.
Gainesville, FloridaAges 18 years+ - NCT05792150Recruiting
Registry for young women with certain early breast cancer treatments
This registry collects information from pre- or perimenopausal women with early breast cancer who are treated with standard care, plus tumor testing like MammaPrint®. It may help doctors better understand which treatments work best for different risk groups.
Baden-Baden, Baden-WurttembergAges 18–60 - NCT06658912Recruiting
Weight loss program for breast cancer survivors
This study tests a weight loss program designed specifically for women who have finished breast cancer treatment. It aims to help improve overall health after cancer.
Durham, North CarolinaAges 21–90 - NCT06106477Recruiting
Intermittent fasting for women with early breast cancer
This trial studies whether a 14-hour night fast and 10-hour eating window can improve inflammation markers and quality of life in women with HR+/HER2- early breast cancer. You would start the fasting routine within three months of beginning hormone therapy.
Milwaukee, WisconsinAges 18 years+ - NCT06790693RecruitingPhase 3
Inavolisib plus hormone therapy for advanced breast cancer
This trial tests a new targeted therapy, inavolisib, combined with standard hormone therapy and a CDK4/6 inhibitor for people with a specific genetic mutation (PIK3CA) in their hormone receptor-positive, HER2-negative advanced breast cancer that has not been treated before. It compares this combination to a placebo plus the same standard treatments.
Goodyear, ArizonaAges 18 years+ - NCT07743944Recruiting
Breast cancer second-line treatment patterns in China
This study looks at how doctors in China treat hormone receptor-positive, HER2-negative breast cancer that has spread, when patients are starting their second line of therapy. The goal is to learn more about real-world treatment patterns and results, which may help you and your doctor make more informed treatment decisions.
Nanjing, JiangsuAges 18 years+ - NCT07743827Recruiting
Olanzapine-based steroid-sparing anti-nausea treatment for breast cancer
This trial tests a new anti-nausea medicine combination for breast cancer patients getting AC chemotherapy, specifically designed for those with diabetes, obesity, or other metabolic issues. It aims to reduce the need for steroids, which can be riskier for these patients.
Alexandria, Alexandria GovernorateAges 18–70 - NCT07739511RecruitingPhase 1/Phase 2
Oral paclitaxel for HER2-positive breast cancer before surgery
This trial tests an oral form of paclitaxel combined with standard HER2 therapy given before surgery for HER2-positive breast cancer. It aims to find the best dose and see how well it works.
Guiyang, GuizhouAges 18–70 - NCT07739485RecruitingPhase 1/Phase 2
Oral paclitaxel before surgery for triple-negative breast cancer
This trial tests an oral form of a common chemo drug, paclitaxel, given before surgery for triple-negative breast cancer. It aims to find the best dose and see how well it shrinks tumors.
Guiyang, GuizhouAges 18–70
Hear when a new Breast trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for breast?
- Yes. Clin2 currently lists 2,691 recruiting breast studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a breast trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a breast trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.